Title: A Study on Prevention of Bleeding Complications Using Lusutrombopag for Safe RFA in
Patients with Hepatocellular Carcinoma with Low Platelet Counts: Prospective Observational
Study.
Version: 2 Date: 09 May 2023
Reviewer's report:
1. Data regarding hepatoxicity of Lusutrombopag especially in cirrhotic patients need to be
introduced.
2. Authors need to clarify the exact enrollment criteria, exclusion criteria, and the study protocol
(with exact digits). If this study is prospective study, authors are definitely required to answer
to this question. For example, to whom and when was Lusutrombopag administered? What
was the exact criteria for lustrombopag administration and what’s the criteria for PLT and also
avoidance?
3. Authors are recommended to demonstrate the safety profile of Lustrombopag (adverse events
including hepatoxicity, unexpected patients’ symptoms or events, thrombosis, etc.)
4. In general, authors are highly recommended to polish this research paper including
manuscript, tables and also figures so that readers can understand what authors are trying to tell.
5. Introduction) It is hard to understand why the authors emphasized about the treatment of HCV,
and HBV and increase in NASH. Is this related to this article?
6. Introduction) Previous study results concerning bleeding or complication risk when patient
has low PLT level needs to be specifically introduced.
7. Introduction) It is hard to understand the meaning of this sentence “Lusutrombopag was
administered to patients whose PLT count tended to decline, cases where the PLT count just
before administration was > 50,000, cases that had previously recorded # 50,000, and those that
fluctuated around 50,000, or were greater than, but around, 50,000.”
8. Results) What’s the tumor staging system the authors used and how could stage III, and IV
patient undergo RFA?
9. Results) How can patient with Child Pugh Score C undergo RFA?
10. Results) “The PLT level increased from 4.4x104 ± 1.4x104 to 8.6 x104±2.5x104 µL-1 after
administration of lusutrombopag (Fig. 1).” When did the authors measure PLT count and was
there any statistical significance?
Title: A Study on Prevention of Bleeding Complications Using Lusutrombopag for Safe RFA in
Patients with Hepatocellular Carcinoma with Low Platelet Counts: Prospective Observational
Study.
Version: 2 Date: 09 May 2023
Reviewer's report:
1. Data regarding hepatoxicity of Lusutrombopag especially in cirrhotic patients need to be
introduced.
2. Authors need to clarify the exact enrollment criteria, exclusion criteria, and the study protocol
(with exact digits). If this study is prospective study, authors are definitely required to answer
to this question. For example, to whom and when was Lusutrombopag administered? What
was the exact criteria for lustrombopag administration and what’s the criteria for PLT and also
avoidance?
3. Authors are recommended to demonstrate the safety profile of Lustrombopag (adverse events
including hepatoxicity, unexpected patients’ symptoms or events, thrombosis, etc.)
4. In general, authors are highly recommended to polish this research paper including
manuscript, tables and also figures so that readers can understand what authors are trying to tell.
5. Introduction) It is hard to understand why the authors emphasized about the treatment of HCV,
and HBV and increase in NASH. Is this related to this article?
6. Introduction) Previous study results concerning bleeding or complication risk when patient
has low PLT level needs to be specifically introduced.
7. Introduction) It is hard to understand the meaning of this sentence “Lusutrombopag was
administered to patients whose PLT count tended to decline, cases where the PLT count just
before administration was > 50,000, cases that had previously recorded # 50,000, and those that
fluctuated around 50,000, or were greater than, but around, 50,000.”
8. Results) What’s the tumor staging system the authors used and how could stage III, and IV
patient undergo RFA?
9. Results) How can patient with Child Pugh Score C undergo RFA?
10. Results) “The PLT level increased from 4.4x104 ± 1.4x104 to 8.6 x104±2.5x104 µL-1 after
administration of lusutrombopag (Fig. 1).” When did the authors measure PLT count and was
there any statistical significance?
Please review this paper.
user
Title: A Study on Prevention of Bleeding Complications Using Lusutrombopag for Safe RFA in
Patients with Hepatocellular Carcinoma with Low Platelet Counts: Prospective Observational
Study.
Version: 2 Date: 09 May 2023
Reviewer's report:
1. Data regarding hepatoxicity of Lusutrombopag especially in cirrhotic patients need to be
introduced.
2. Authors need to clarify the exact enrollment criteria, exclusion criteria, and the study protocol
(with exact digits). If this study is prospective study, authors are definitely required to answer
to this question. For example, to whom and when was Lusutrombopag administered? What
was the exact criteria for lustrombopag administration and what’s the criteria for PLT and also
avoidance?
3. Authors are recommended to demonstrate the safety profile of Lustrombopag (adverse events
including hepatoxicity, unexpected patients’ symptoms or events, thrombosis, etc.)
4. In general, authors are highly recommended to polish this research paper including
manuscript, tables and also figures so that readers can understand what authors are trying to tell.
5. Introduction) It is hard to understand why the authors emphasized about the treatment of HCV,
and HBV and increase in NASH. Is this related to this article?
6. Introduction) Previous study results concerning bleeding or complication risk when patient
has low PLT level needs to be specifically introduced.
7. Introduction) It is hard to understand the meaning of this sentence “Lusutrombopag was
administered to patients whose PLT count tended to decline, cases where the PLT count just
before administration was > 50,000, cases that had previously recorded # 50,000, and those that
fluctuated around 50,000, or were greater than, but around, 50,000.”
8. Results) What’s the tumor staging system the authors used and how could stage III, and IV
patient undergo RFA?
9. Results) How can patient with Child Pugh Score C undergo RFA?
10. Results) “The PLT level increased from 4.4x104 ± 1.4x104 to 8.6 x104±2.5x104 µL-1 after
administration of lusutrombopag (Fig. 1).” When did the authors measure PLT count and was
there any statistical significance?
assistant